Title : Synergistic anticancer efficacy of MEK inhibition and dual PI3K/mTOR inhibition in castration-resistant prostate cancer.

Pub. Date : 2015 Nov

PMID : 26250606






3 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 GSK2126458 decreased phospho-AKT while increasing phospho-ERK and AZD6244 decreased phospho-ERK efficiently while increasing phospho-AKT. AZD 6244 AKT serine/threonine kinase 1 Homo sapiens
2 The combination of GSK2126458 and AZD6244 decreased both phospho-AKT and phospho-ERK effectively in vitro and in vivo. AZD 6244 AKT serine/threonine kinase 1 Homo sapiens
3 CONCLUSIONS: The combination of GSK2126458 and AZD6244 blocks both the RAS/RAF/MEK/ERK and PI3K/AKT/mTOR pathways simultaneously and is an effective strategy for the treatment of CRPCs. AZD 6244 AKT serine/threonine kinase 1 Homo sapiens